Abbott Laboratories Corporation

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Grenier, Frank C.

Ali, Salman

Workman, Ryan F.

Syed, Hina N.

Frank C Grenier

Ryan F Workman

Hina N Syed

Salman Ali

Joan D Tyner

David J Hawksworth

Robert N Ziemann

Lawrence Kolaczkowski

Larry G Birkenmeyer

Bailin Tu

Terry A Pry

Allan H Smith

Thomas F Holzman

Alan C Tsurutani

Suresh M Desai

Bernhard K Mueller

Susan E Brophy

Qiaoqiao Ruan

Bryan C Tieman

Sergey Y Tetin

Robert William Siegel

Andreas Popp

Gangamani S Beligere

Elaine Marie Brate

Edward T Olejniczak

Kevin R Rupprecht

Tracey D Rae

David R Blonski

Merry E Bergmann

Julie A Luczkiw

Ryan M Bonn

Shamila Manoj

Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.

Composition and method for the diagnosis and treatment of iron-related disorders

The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Antibodies that bind to mammalian NGAL and uses thereof

The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and an alcohol. Other aspects of the invention include related immunoassays and test kits.

Non-denaturing lysis reagent

An improved extractive reagent composition and method for extracting an immunosuppressant drug, such as sirolimus, tacrolimus or cyclosporine, from blood samples while yielding a test sample extract that has low vapor pressure and is compatible with immunoassay components. The inventive reagent composition comprises dimethyl sulfoxide (DMSO), at least one divalent metal salt and water. The sample extracts resulting from use of each of these combinations have low vapor pressure and are compatible with immunochemistry assays.

Immunosuppressant drug extraction reagent for immunoassays

The invention provides methods of preparing a test sample for use in an assay for detecting an analyte bound by an intracellular ligand. The methods typically involve contacting the test sample with an assay reagent comprising: a lysis reagent; and a protease that has proteolytic activity for said intracellular ligand; to form a mixture compatible for use in an immunoassay without subsequent extraction steps. Other aspects of the invention include related immunoassays and test kits.

Diagnostic test for the detection of a molecule or drug in whole blood

A composition comprising neutrophil gelatinase-associated lipocalin (NGAL), which has been enriched from urine, has a molecular weight of about 24.9 kDa to about 25.9 kDa, and comprises a plurality of isoforms having isoelectric points (pIs) ranging from about 5.9 to about 9.1; a composition comprising NGAL, which has been enriched from recombinant Chinese hamster ovary (CHO) cells, has a molecular weight of about 25.9 kDa to about 27.9 kDa, and comprises a plurality of isoforms having pIs ranging from about 5.6 to about 9.1; a method of obtaining from urine a composition comprising a plurality of isoforms of NGAL, which method comprises enriching NGAL in urine without separating molecules based on charge; a method of obtaining from recombinant CHO cells a composition comprising a plurality of isoforms of NGAL, which method comprises enriching NGAL in a composition without separating molecules based on charge; and a method of analyzing NGAL isoforms enriched from urine or recombinant CHO cells comprising analyzing an enriched composition comprising NGAL isoforms by two-dimensional electrophoresis and Western blot.

Neutrophil gelatinase-associated lipocalin (NGAL) protein isoforms enriched from urine and recombinant chinese hamster ovary (CHO) cells and related compositions, antibodies, and methods of enrichment, analysis and use

The present invention is directed to an in vitro aqueous composition comprising a drug, preferably tacrolimus or rapamycin, having enhanced stability. The invention utilizes a binding protein, preferably FKBP, to stabilize the drug in an aqueous matrix.

Stabilized standards and calibrators containing rapamycin and

The present invention is directed to an in vitro aqueous composition comprising a drug, preferably tacrolimus or rapamycin, having enhanced stability. The invention utilizes a binding protein, preferably antibodies to tacrolimus or rapamycin, to stabilize the drug in an aqueous matrix.

Stabilized standards and calibrators containing rapamycin and tacrolimus

A stabilized, aqueous composition containing FK506. FK506 degrades rapidly in most aqueous matrices. The rate of degradation is decreased in the presence of unfixed blood cells or fragments of blood cells from human or animal sources. A number of matrices using blood components are possible. Blood can be used directly or the blood cells can be lysed. The blood is diluted with a solution of an alkali halide.

Stable aqueous FK506 standards

A method for performing a diagnostic immunoassay by solid phase separation for digoxin. To a reaction mixture of a test sample and labeled anti-digoxin antibody, which forms a complex of any digoxin present in the test sample, is added a solid phase material having an immobilized ouabain triacetate derivative compound capable of binding any excess labeled antibody. The solid phase material is chosen to rapidly settle whereby a solid and liquid phase is formed. The liquid phase can then be extracted to measure the amount of digoxin-labeled antibody present therein. Ouabain triacetate derivative compounds possess sufficient affinity for anti-digoxin antibodies, and are therefore useful in a solid phase separation based digoxin immunoassay for settling out such antibodies without contributing to undesired background interference. These compounds are also less deleterious to assay performance because of low recognition when leached from the solid phase matrix thereby providing solid phase material with extended shelf life.

Ouabain triacetate derivative compounds

Diagnostic immunoassay by solid phase separation for digoxin

Growing community of inventors

Libertyville, IL, United States of America

Frank C Grenier